Clinical study of Wendan Decoction in improving erythrocyte immune function in patients with lung cancer complicated with hyperlipidemia
Not Applicable
- Conditions
- lung cancer
- Registration Number
- ITMCTR2000003826
- Lead Sponsor
- Shanghai Traditional Chinese Medicine Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
(1) Patients with non-small cell lung cancer were diagnosed by pathology or cytology;
(2) Aged 18 to 80 years old (including 18 and 80 years old);
(3) The expected survival time was more than 3 months;
(4) Karnofsky score >=60;
(5) No TCM decoction pieces or granules were used within 3 months before treatment;
(6) Volunteer to participate in this study, can follow-up.
Exclusion Criteria
1. Combined with other primary malignant tumors;
2. Patients with uncontrollable severe infection, hypertension, diabetes and liver and kidney dysfunction;
3. Pregnant and lactating women;
5. Patients or family members are not willing to sign the informed consent or do not agree with the author;
7. Any situations that researchers decide to exclude.
Study & Design
- Study Type
- Observational study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method blood lipid;
- Secondary Outcome Measures
Name Time Method